aldoxorubicin + N-803 + PD-L1 t-haNK

This therapy is a **combination regimen** consisting of three investigational agents: - **Aldoxorubicin**, a prodrug of the chemotherapy doxorubicin that preferentially targets tumors by binding to albumin, which accumulates in tumors, and is released in the acidic microenvironment, delivering cytotoxic doxorubicin directly to tumor cells[1]. - **N-803**, also known as Anktiva, is a recombinant IL-15 superagonist cytokine that enhances the activation and proliferation of immune effector cells, notably natural killer (NK) cells and CD8+ T cells, thereby potentiating anti-tumor immunity[2][5]. - **PD-L1 t-haNK**, an engineered natural killer (NK) cell line expressing a high-affinity CD16, ER-retained IL-2, and a chimeric antigen receptor (CAR) targeting PD-L1, enabling direct cytolysis of PD-L1-expressing tumor cells and selective lysis of immunosuppressive myeloid-derived suppressor cells[3][6]. The combination is under investigation primarily in advanced metastatic or recurrent pancreatic cancer, showing early evidence of durable responses and enhanced tumor cytolysis through complementary immunomodulatory and cytotoxic mechanisms[1][4][7][9]. Preclinical and early clinical data suggest potential for improved outcomes over standard-of-care, particularly where other therapies have failed.

Other names

aldoxorubicin HClIL-15 superagonist N-803IL15 superagonist N-803IL 15 superagonist N-803AnktivaPD-L1 targeting high-affinity NK cellPD-L-1 targeting high-affinity NK cellPD-L 1 targeting high-affinity NK cellPD-L1-targeted t-haNKPD-L-1-targeted t-haNKPD-L 1-targeted t-haNK